Latest News and Press Releases

In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction...

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical...

Novartis secured 79.6 percent acceptance by MorphoSys shareholders during the initial acceptance period, reaching the minimum 65% acceptance thresholdSettlement of the shares tendered during the...

Primary results of the Scemblix® ASC4FIRST pivotal Phase III study in first-line Ph+ CML-CP supporting third US FDA Breakthrough Therapy designation, to be detailed in the ASCO Press Program and the...

There is currently no evidence-based treatment for the smallest babies with malaria The CALINA study tested a new ratio and dose of Coartem® (artemether- lumefantrine) to account for metabolic...

Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic...

Ad-hoc-Mitteilung gemäss Art. 53 KRDer Nettoumsatz wuchs im ersten Quartal um +11% (kWk1, +10% USD), das operative Kernergebnis verbesserte sich um +22% (kWk, +16% USD)Die wichtigsten...

Annonce événementielle au sens de l’art. 53 RCRésultats du premier trimestre (T1)Chiffre d’affaires net en hausse de +11% (tcc1, +10% USD) et du résultat opérationnel core, de +22% (tcc, +16% USD) Les...

Ad hoc announcement pursuant to Art. 53 LRQ1 net sales grew +11% (cc1, +10% USD) with core operating income up +22% (cc, +16% USD) Key growth drivers continued strong sales momentum including Entresto...

Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis...